Small Molecules in Oncology

This book, written by respected experts, discusses in detail the latest developments in targeted oncology therapy using small molecules. It covers a wide range of small molecules, including tyrosine kinase inhibitors, mTOR, MEK, PARP, and multikinase inhibitors, as well as cell cycle and NTRK intera...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
Άλλοι συγγραφείς: Martens, Uwe M. (Επιμελητής έκδοσης, http://id.loc.gov/vocabulary/relators/edt)
Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
Γλώσσα:English
Έκδοση: Cham : Springer International Publishing : Imprint: Springer, 2018.
Έκδοση:3rd ed. 2018.
Σειρά:Recent Results in Cancer Research, 211
Θέματα:
Διαθέσιμο Online:Full Text via HEAL-Link
LEADER 03211nam a2200481 4500
001 978-3-319-91442-8
003 DE-He213
005 20191027151700.0
007 cr nn 008mamaa
008 180801s2018 gw | s |||| 0|eng d
020 |a 9783319914428  |9 978-3-319-91442-8 
024 7 |a 10.1007/978-3-319-91442-8  |2 doi 
040 |d GrThAP 
050 4 |a RC254-282 
072 7 |a MJCL  |2 bicssc 
072 7 |a MED062000  |2 bisacsh 
072 7 |a MJCL  |2 thema 
082 0 4 |a 616.994  |2 23 
245 1 0 |a Small Molecules in Oncology  |h [electronic resource] /  |c edited by Uwe M. Martens. 
250 |a 3rd ed. 2018. 
264 1 |a Cham :  |b Springer International Publishing :  |b Imprint: Springer,  |c 2018. 
300 |a VIII, 276 p. 34 illus., 19 illus. in color.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
490 1 |a Recent Results in Cancer Research,  |x 0080-0015 ;  |v 211 
505 0 |a Erlotinib -- Lapatinib -- Sorafenib -- Regorafenib -- Crizotinib -- Cabozantinib -- Vemurafenib -- Trametinib -- Everolimus -- Vismodegib -- Larotrectinib -- Palbociclib -- Taselisib -- Cobimetinib -- Lenvatinib -- Afatinib -- Olaparib -- Gefitinib -- Ceritinib. . 
520 |a This book, written by respected experts, discusses in detail the latest developments in targeted oncology therapy using small molecules. It covers a wide range of small molecules, including tyrosine kinase inhibitors, mTOR, MEK, PARP, and multikinase inhibitors, as well as cell cycle and NTRK interacting agents. For each molecule, aspects such as the chemical structure, mechanism of action, drug targets, drug interactions, preclinical studies, clinical trials, treatment applications, and toxicity are discussed. Extensive research into the molecular mechanisms of cancer has heralded a new age of targeted therapy. The field of personalized cancer therapy is now growing rapidly, and the advances being made will mean significant changes in the treatment algorithms for cancer patients. Numerous novel targets that are crucial for the survival of cancer cells can be attacked by small molecules such as protein tyrosine kinase inhibitors. This book is the third edition of Small Molecules in Oncology, but has now been divided into two volumes, with the other volume focusing specifically on small molecules in hematology. . 
650 0 |a Oncology  . 
650 0 |a Cancer research. 
650 1 4 |a Oncology.  |0 http://scigraph.springernature.com/things/product-market-codes/H33160 
650 2 4 |a Cancer Research.  |0 http://scigraph.springernature.com/things/product-market-codes/B11001 
700 1 |a Martens, Uwe M.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer eBooks 
776 0 8 |i Printed edition:  |z 9783319914411 
776 0 8 |i Printed edition:  |z 9783319914435 
776 0 8 |i Printed edition:  |z 9783030082574 
830 0 |a Recent Results in Cancer Research,  |x 0080-0015 ;  |v 211 
856 4 0 |u https://doi.org/10.1007/978-3-319-91442-8  |z Full Text via HEAL-Link 
912 |a ZDB-2-SME 
950 |a Medicine (Springer-11650)